


A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions by Industry



News highlights:

- Juno Therapeutics acquired AbVitro, a Harvard spinout, focused on sequencing single cells in a deal worth \$125 million. Under the agreement, Juno is paying \$78 million and about 1.3 million shares.
- Wellpepper, a clinically validated platform for patient engagement, was selected by Evergreen Health as the mobile engagement solution for all total joint replacement and musculoskeletal care plans. Patients with musculoskeletal issues that require surgery or rehabilitation will use Wellpepper on their mobile devices to track their outcomes and adhere to their care plans.
- EveryMove has shifted its business strategy and announced a new product that helps health plans with member engagement and behavior change, called Tandem. EveryMove also announced its first customer for Tandem, Premera Blue Cross.
- Kaiser Permanente set to acquire Group Health, expanding Kaiser’s geographic reach and boosting its health plan membership by 6%. The deal is expected to close this year.

Deal highlights:


- **Blaze Bioscience** \$991,000 (Debt)
- **Stemgenics** \$930,000 (Equity)
- **Vicis** \$8 million (Equity)
- **Clario Medical Imaging** \$185,000 (Equity)
- **ID Genomics** \$50,000 (Equity)
- **Oricula Therapeutics** \$2.06 million (Grant)

2016 running total (Jan-Feb 8th): \$12,216,000


NIH Research and SBIR/STTR Funding

Washington State consistently ranks in the top 10 for NIH research grants but ranks 12th for Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) grants in 2015.

2015 Award Rankings




Share of Total Federal Funds Awarded, 2015 by State




Washington State received 4.2% of 2015 research funds awarded but only 2.4% of SBIR/STTR dollars. By comparison, Oregon received only 1.1% of research funding but matched WA State in 2015 SBIR/STTR funding.


In comparison to MA and OR, WA State obtains disproportionately lower SBIR/STTR funding relative to overall research funding



2014 SBIR Success Rates



2014 STTR Success Rates



- WA State applicants saw lower Phase II proposal success rates compared to peer States.
- These data suggest an opportunity to leverage non-dilutive federal funds to more efficiently translate research funding to commercialized technologies in the State.

This data was compiled from the NIH Research Portfolio Online Reporting Tools (RePORT), <https://report.nih.gov/award/index.cfm>, and NIH SBIR/STTR Award Data, <https://sbir.nih.gov/statistics/award-data>.

Washington-based Life Science Transactions 2016

Date	Company	Type	Amount
01/12/16	Blaze Bioscience	Debt	\$991,000
01/14/16	Stemgenics	Equity	\$930,000
01/20/16	Vicis	Seed	\$8,000,000
01/25/16	Clario Medical Imaging	Equity	\$185,000
02/02/16	ID Genomics	Equity	\$50,000
02/02/16	Oricula Therapeutics	Grant	\$2,060,000
2016 Running Total as of February 8, 2016			\$12,216,000

Washington-based Life Science Transactions 2015

Date	Company	Type	Amount	Date	Company	Type	Amount
01/22/15	Alder Biopharmaceuticals	Second public offering	\$203,600,000	06/29/15	Nexgenia	Equity	\$1,617,582
01/22/15	Adaptive Biotechnologies	Series E	\$93,750,000	06/30/15	Vera Whole Health, Inc	Debt	\$2,000,000
01/28/15	Vesiflo	Convertible note	\$650,000	07/13/15	Arivale	Series B	\$36,000,000
01/30/15	MalarVx, Inc	Equity	\$110,000	07/14/15	Cytodyn	Equity	\$1,972,500
02/05/15	Alpine Immune Sciences	Seed	\$1,300,000	07/14/15	RF Surgical Systems	Acquisition	\$235,000,000
02/05/15	M3 Biotechnology	Equity	\$150,000	07/21/15	Deep Domain	Equity	\$260,507
02/10/15	Valant Medical Solutions	Venture Equity	\$285,350	07/31/15	Qliance Medical Management	Debt	\$2,676,730
02/13/15	Stasys Medical	Series A	\$160,000	08/07/15	Precision Image Analysis	Equity	\$60,348
02/18/15	StratoScientific	Venture Equity	\$550,000	08/11/15	Vicis	Venture Equity	\$1,500,000
02/23/15	Dendreon	Acquisition	\$495,000,000	08/12/15	Marina Biotech	Equity	\$1,100,000
03/06/15	Cerevast Therapeutics	Series C	\$1,375,000	08/13/15	Bloomingdale Memory Care	Equity	\$3,373,525
03/09/15	KinDex Pharmaceuticals	Series A	\$500,000	08/17/15	OtoNexus Medical Technologies	Debt	\$754,990
03/11/15	Cardiac Dimensions	Venture Equity	\$15,200,000	08/18/15	Immusoft	Debt	\$375,000
03/15/15	Medical Mirror Systems	Equity	\$250,000	08/19/15	Sound Pharmaceuticals	Debt	\$300,000
03/19/15	Nortis	Venture Equity	\$408,845	08/21/15	Navigating Cancer	Venture Equity	\$6,605,573
03/20/15	Healthentic	Series C	\$3,750,000	08/28/15	Aqueduct Critical Care	Equity	\$3,712,304
03/20/15	StratoScientific	Venture Equity	\$150,000	09/02/15	Kona Medical	Debt	\$10,000,300
03/25/15	Cadence Biomedical	Equity	\$959,578	09/14/15	Seattle Genetics	Second public offering	\$525,000,000
04/08/15	NuvoMed	Equity	\$390,637	09/14/15	Impel Neuropharma	Equity	\$1,257,927
04/10/15	Cardeas Pharma	Series B	\$3,500,000	09/18/15	Impel Neuropharma	Equity	\$4,000,000
04/13/15	Carena	Debt	\$500,000	09/21/15	Cardiac Insight	Undisclosed	\$3,500,000
04/17/15	X2 Biosystems	Venture Equity	\$350,000	09/22/15	Just Biotherapeutics	Series A	\$15,000,000
04/23/15	Deep Domain	Venture Equity	\$30,000	09/24/15	VDA Pharma	Debt	\$55,000
04/24/15	Mpirica Health	Series A	\$1,600,000	09/24/15	Joylux	Seed	\$3,000,000
05/01/15	Mirabilis Medica	Debt	\$2,920,000	09/30/15	Accelerator Corporation	Venture Equity	\$11,700,000
05/06/15	Adaptive Biotechnologies	Series F	\$195,000,000	10/02/15	Spiral Genetics	Debt	\$200,000
05/06/15	Theracione Sciences	Venture Equity	\$3,080,000	10/04/15	Cytodyn	Equity	\$2,693,800
05/06/15	Cyrus Biotechnology	Debt	\$850,000	10/15/15	Global Health Vaccine Center of Innovation	Partnership	\$9,500,000
05/06/15	InDemand Interpreting	Venture Equity	\$4,000,000	10/19/15	Novuson Surgical	Equity	\$500,000
05/14/15	Cytodyn	Debt	\$3,281,050	10/27/15	Alpine Immune Sciences	Partnership	\$5,000,000
05/18/15	Tissue Regeneration Systems	Debt	\$2,093,182	10/27/15	Park Boulevard Memory Care, LLC	Equity	\$3,524,925
05/19/15	KPI Therapeutics	Equity	\$27,000	10/30/15	Metheor Therapeutics	Equity	\$90,000
05/21/15	Ventec Life Systems	Venture Equity	\$8,192,480	11/04/15	Clarity Health	Acquisition	Undisclosed
05/27/15	BioViva USA	Equity	\$250,000	11/11/15	Aminex Therapeutics	Series A	\$4,000,000
06/02/15	C-SATS	Venture Equity	\$2,500,000	11/11/15	Mpirica Health	Venture Equity	\$400,000
06/03/15	Magnolia Medical Technologies	Venture Equity	\$6,235,322	11/13/15	Qliance Medical Management	Equity	\$450,000
06/04/15	Carena	Series B	\$13,300,000	11/16/15	Implicit Bioscience	Equity	\$50,800
06/05/15	Valant Medical Solutions	Venture Equity	\$3,000,000	11/20/15	M3 Biotechnology	Equity	\$3,500,000
06/11/15	Glycostasis	Equity	\$149,998	11/25/15	OtoNexus Medical Technologies	Debt	\$1,403,080
06/16/15	Altius Institute for Biomedical Sciences	Partnership	\$95,000,000	12/01/15	Universal Cells	Partnership	\$5,500,000
06/16/15	Remote Medical International	Partnership	\$95,000,000	12/01/15	EndoGastric Solutions	Equity	\$50,000,000
06/17/15	Stratos Genomics	Series B	\$19,999,976	12/04/15	Breast Microseed	Debt	\$500,000
06/20/15	Global Innovation Exchange	Partnership	\$45,000,000	12/16/15	Matrix Genetics	Debt	\$1,600,000
06/20/15	Vicis	Seed	\$1,600,000	12/23/15	Switch Healthcare	Equity	\$300,000
06/22/15	Qliance Medical Management	Debt	\$520,753	12/24/15	Nohla Therapeutics	Equity	\$21,000,000
06/24/15	Nativis	Venture Equity	\$725,000	12/24/15	Nativis	Equity	\$250,000
06/24/15	Cadence Biomedical	Series B	\$1,200,000	12/29/15	PhaseRx	Debt	\$4,000,000
06/25/15	Blaze Bioscience	Equity	\$85,400				
06/28/15	Juno Therapeutics	Partnership	\$1,000,000,000				
				2015 Total			\$3,263,814,462

Washington-based Life Science Transactions 2013

Date	Company	Type	Amount
01/03/13	Qliance Medical Management	Series D	\$8,650,000
01/04/13	RF Surgical Systems	Series A	\$120,000
01/30/13	Immune Design	3rd installment series B	\$10,625,000
01/31/13	FlexMinder	Series A	\$1,200,000
02/08/13	Kineta	Venture Equity	\$2,737,052
02/14/13	X2 Biosystems	Undisclosed	\$2,000,000
02/15/13	Healionics	Undisclosed	\$50,000
02/20/13	Miribilis Medica	Undisclosed	\$120,000
02/20/13	Ventec Life Systems	Venture Equity	\$6,800,000
02/22/13	Blaze Bioscience	Series A	\$8,500,000
02/22/13	Endogastric Solutions	Debt	\$10,000,000
02/27/13	Resolve Therapeutics	Partnership	\$8,000,000
03/01/13	Cadence Biomedical	Venture Equity	\$213,000
04/01/13	EveryMove	Series A	\$3,500,000
04/03/13	Avado	Seed equity	\$1,000,000
03/05/13	PreSage Biosciences	Partnership	\$13,000,000
03/12/13	Appature	Acquisition	NA
03/12/13	Spiral Genetics	Venture Equity	\$3,200,000
03/25/13	Theraclone Sciences	Series B	\$14,000,000
04/02/13	Cardiac Dimensions	Debt	\$2,730,000
04/02/13	Cerevast Therapeutics	Venture Equity	\$1,500,000
04/11/13	Atossa Genetics	Venture Equity	\$100,000
04/17/13	Beat BioTherapeutics	Debt	\$2,500,000
04/18/13	NuvoMed	Equity	\$485,000
04/19/13	Miribilis Medica	Debt	\$100,000
05/13/13	NanoString Technologies	Venture Equity	\$150,000
05/23/13	Cardeas Pharma	Series B	\$34,000,000
05/23/13	Valant Medical Solutions	Venture Equity	\$784,000
05/24/13	Remote Medical International	Venture Equity	\$8,000,000
05/24/13	Ekos	Acquisition	\$180,000,000
05/28/13	VentriPoint	Debt	\$750,000
05/30/13	Cadence Biomedical	Grant	\$1,000,000
05/30/13	Oncothyreon	Stock sale	\$10,000,000
06/03/13	AVM Biotechnology	Venture Equity	\$708,000
06/05/13	Mobisante	Venture Equity	\$4,200,000
06/06/13	Cheetah Medical	Venture Equity	\$14,500,000
06/12/13	Immune Design	Partnership	\$10,000,000
06/14/13	Miribilis Medica	Venture Equity	\$7,000,000
06/18/13	Exo Labs	Undisclosed	\$836,000
06/20/13	X2 Biosystems	Venture Equity	\$1,200,000
06/25/13	Seattle Genetics - Bayer deal	Partnership	\$20,000,000
06/26/13	NanoString Technologies	IPO	\$54,000,000
06/27/13	Lifecom	Series A	\$1,100,000
06/28/13	Blaze Biosciences	Series B	\$8,100,000
07/12/13	PhaseRx	Debt	\$500,000
07/12/13	X2 Biosystems	Debt	\$720,000
08/15/13	Project Violet	Undisclosed	\$20,000,000
08/16/13	Tissue Regeneration Systems	Venture Equity	\$4,600,000
08/19/13	Allozyne	Debt	\$2,500,000
09/03/13	Oncofactor	Venture Equity	\$1,000,000
09/03/13	Alpine Bioventures	Equity	\$5,000,000
09/09/13	Stratos Genomics	Venture Equity	\$2,000,000
09/16/13	Adaptive Biotechnologies	Grant	\$2,530,000
09/20/13	Integrated Diagnostics	Equity	\$1,500,000
10/03/13	PhaseRx	Debt	\$1,400,000
10/10/13	Kineta	Venture Equity	\$760,000
10/15/13	Qliance Medical Management	Venture Equity	\$5,500,000
10/16/13	Sound Pharmaceuticals	Venture Equity	\$6,000,000
10/16/13	Cardiac Dimensions	Debt	\$555,000
10/21/13	Kona Medical	Venture Equity	\$10,000,000
10/29/13	Avado	Acquisition	\$25,000,000
10/30/13	Immune Design	Venture Equity	\$49,000,000
11/04/13	Kineta	Grant	\$6,800,000
11/15/13	Cell Therapeutics	Partnership	\$60,000,000
11/26/13	Cerevast Therapeutics	Debt	\$1,780,000
11/27/13	Impel NeuroPharma	Venture Equity	\$2,640,000
12/05/13	Clarity Health	Series B	\$6,600,000
12/03/13	Blaze Bioscience	Series B*	\$900,000
12/05/13	Juno Therapeutics	Series A	\$120,000,000
12/10/14	Integrated Diagnostics	Seed equity	\$300,000
12/27/13	X2 Biosystems	Venture Equity	\$5,000,000
2013 Total			\$800,043,052

Washington-based Life Science Transactions 2014

Date	Company	Type	Amount
01/07/14	Cardiac Dimensions	Debt	\$367,000
01/08/14	Seattle Genetics	Partnership	\$25,000,000
01/13/14	Juno Therapeutics	Series A extension	\$25,000,000
01/13/14	ActX	Seed equity	\$1,900,000
01/14/14	NovuMed	Undisclosed	\$535,000
01/21/14	Seattle Genetics	Partnership	\$9,000,000
02/04/14	Acucela	IPO (Japan)	\$162,000,000
02/12/14	Cardiac Dimensions	Debt	\$456,000
02/12/14	Nativis	Venture Equity	\$9,160,000
03/05/14	Immunexpress	Venture Equity	\$6,000,000
03/14/14	Kineta	Venture Equity	undisclosed
03/14/14	Nortis	Undisclosed	\$1,200,000
03/17/14	CadenceMD	Debt	\$55,000
03/20/14	Cardiac Dimensions	Debt	\$380,000
03/25/14	Clarity Health	Venture Equity	\$836,000
03/25/14	BioLife Solutions	IPO	\$15,400,000
03/25/14	FlexMinder	Series A	\$1,200,000
03/26/14	KinDex Pharmaceuticals	Series A	\$5,000,000
04/07/14	Adaptive Biotechnologies	Series C&D	\$105,000,000
04/09/14	Oricula Therapeutics	Seed equity	\$122,000
04/10/14	Tissue Regeneration Systems	Debt	\$1,500,000
04/14/14	JeNu Biosciences	Debt	\$1,480,000
04/14/14	Etubics	Seed	\$4,400,000
04/16/14	Cardiac Dimensions	Venture Equity	\$20,000,000
04/18/14	X2 Biosystems	Debt	\$2,510,000
04/24/14	Juno Therapeutics	Series A extension	\$31,000,000
04/29/14	Integrated Diagnostics	Debt	\$17,000,000
04/29/14	Integrated Diagnostics	Series B	\$30,250,000
05/08/14	Alder Biopharmaceuticals	IPO	\$80,000,000
05/13/14	Stratos Genomics	Series B	\$10,000,000
05/14/14	PharmaIN	Venture Equity	\$1,500,000
05/15/14	AVM Biotechnology	Series B	\$1,500,000
05/16/14	Kineta	Equity	\$1,627,498
06/06/14	NanoString Technologies	Partnership	\$5,750,000
06/15/14	Cardiac Insight	Series B	\$7,000,000
07/01/14	Pregenen	Acquisition	\$20,000,000
07/11/14	Nortis	Venture Equity	\$1,000,000
07/15/14	Valant Medical	Venture Equity	\$11,000,000
07/18/14	ActX	Seed	\$750,000
07/21/14	Nativis	Undisclosed	\$2,319,000
07/25/14	Immune Design	IPO	\$60,000,000
07/29/14	Accelerator Corporation	Venture Equity	\$51,100,000
07/29/14	Amgen	Closing WA Offices	
07/30/14	Theraclone Sciences	Partnership	undisclosed
07/30/14	Array Health	Debt	\$100,000
07/30/14	Jintronic	Debt	\$772,500
08/04/14	Juno Therapeutics	Series B	\$134,000,000
08/07/14	Immune Design	License	\$168,000,000
08/11/14	Alpine BioSciences	Acquisition	\$27,000,000
08/15/14	Carena	Debt	\$1,995,000
08/21/14	Immusoft	Series A	\$2,300,000
09/02/14	Clarity Health	Venture Equity	\$1,059,352
09/03/14	NovoNordisk	Closing Inflammatory Research Center	
09/10/14	Seattle Genetics	License	\$11,000,000
09/15/14	Tissue Regeneration Systems	Debt	\$500,000
09/23/14	VentriRx Pharmaceuticals	Venture Equity	\$19,300,000
09/26/14	Array Health	Series A	\$13,000,000
10/07/14	Cardiac Dimensions	Venture Equity	\$8,500,000
10/08/14	Blaze BioScience	NCI SBIR Phase II Funding	\$1,500,000
10/09/14	Mirador Biomedical	Acquisition	undisclosed
10/27/14	Limeade	Series C	\$25,000,000
11/05/14	Vicis	Seed	\$2,000,000
11/19/14	IDRI	Contract	\$3,600,000
11/21/14	Aortica	Series A	\$7,000,000
12/09/14	Allen Institute for Cell Science	Paul Allen Donation	\$100,000,000
12/19/14	Juno Therapeutics	IPO	\$264,600,000
12/30/14	Oncogenex	Venture Equity	\$27,000,000
12/30/14	Cerevast Therapeutics	Venture Equity	\$10,000,000
2014 Total			\$1,558,524,350